Neurocrine Biosciences Receivables

Neurocrine Biosciences (NBIX) currently reports a receivables of $960M as of September 2026. That compares with $730M in the prior-year period — up 31.5% year over year. Use the charts on this page to explore Neurocrine Biosciences's receivables history and peer comparisons.

Neurocrine Biosciences's receivables increased from $730M to $960M — a 31.5% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Neurocrine Biosciences reported $960M in receivables as of September 2026. That compares with $730M in the prior-year period — up 31.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $960M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Neurocrine Biosciences, and consider following NBIX for alerts when major investors trade the stock.

Neurocrine Biosciences is classified in the Healthcare sector. On receivables, it currently shows $960M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBIX with unrelated industries.